First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth ◽

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

10.1158/1538-7445.am2013-lb-145 ◽

2013 ◽

Cited By ~ 23

Author(s):

Fabrice Andre ◽

Malcolm Ranson ◽

Emma Dean ◽

Andrea Varga ◽

Ruud van der Noll ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth

Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.11010 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 11010-11010 ◽

Cited By ~ 9

Author(s):

Elaine Kilgour ◽

David Ferry ◽

Matilde Saggese ◽

Hendrik-Tobias Arkenau ◽

Claire Rooney ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth ◽

Biomarker Analysis

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-3334 ◽

2019 ◽

Vol 25 (16) ◽

pp. 4888-4897 ◽

Cited By ~ 37

Author(s):

Rastislav Bahleda ◽

Antoine Italiano ◽

Cinta Hierro ◽

Alain Mita ◽

Andres Cervantes ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Multicenter Phase ◽

621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors

European Journal of Cancer ◽

10.1016/s0959-8049(12)72418-8 ◽

2012 ◽

Vol 48 ◽

pp. 191-192 ◽

Cited By ~ 26

Author(s):

P. ODonnell ◽

J.W. Goldman ◽

M.S. Gordon ◽

K. Shih ◽

Y.J. Choi ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth ◽

Dose Escalation Study

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

Investigational New Drugs ◽

10.1007/s10637-016-0416-x ◽

2017 ◽

Vol 35 (4) ◽

pp. 451-462 ◽

Cited By ~ 21

Author(s):

Hideo Saka ◽

Chiyoe Kitagawa ◽

Yoshihito Kogure ◽

Yasuo Takahashi ◽

Koshi Fujikawa ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Phase I Study ◽

Growth Factor Receptor ◽

Japanese Patients ◽

Solid Tumours ◽

Fibroblast Growth ◽

Abstract 3738: Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877

10.1158/1538-7445.am2017-3738 ◽

2017 ◽

Cited By ~ 1

Author(s):

Peter Ellinghaus ◽

Matthias Ocker ◽

Sebastian Bender ◽

Christoph Kneip ◽

Stuart Ince ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Patient Selection ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Tumor Mrna ◽

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Targeted Oncology ◽

10.1007/s11523-019-00670-4 ◽

2019 ◽

Vol 14 (5) ◽

pp. 591-601 ◽

Cited By ~ 7

Author(s):

Sung-Bae Kim ◽

Funda Meric-Bernstam ◽

Aparna Kalyan ◽

Aleksei Babich ◽

Rong Liu ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Advanced Cancer ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Antibody Drug Conjugate ◽

Antibody Drug

Abstract CT094: Phase I study of fibroblast growth factor receptor 2 antibody-drug conjugate (FGFR2-ADC) BAY 1187982 in patients with advanced cancer

10.1158/1538-7445.am2017-ct094 ◽

2017 ◽

Author(s):

Sung-Bae Kim ◽

Funda Meric-Bernstam ◽

Jordan Berlin ◽

Sabine Wittemer-Rump ◽

Motonobu Osada ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Advanced Cancer ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Antibody Drug Conjugate ◽

Antibody Drug

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3041-7 ◽

2016 ◽

Vol 77 (6) ◽

pp. 1253-1262 ◽

Cited By ~ 4

Author(s):

Toshihiko Doi ◽

Kohei Shitara ◽

Takashi Kojima ◽

Takayuki Yoshino ◽

Aruna Dontabhaktuni ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Japanese Patients ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor ◽

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.2501 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 2501-2501 ◽

Cited By ~ 17

Author(s):

Rastislav Bahleda ◽

Rodrigo Dienstmann ◽

Barbara Adamo ◽

Anas Gazzah ◽

Jeffrey R. Infante ◽

...

Keyword(s):

Growth Factor ◽

Solid Tumors ◽

Phase 1 ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth ◽

Phase 1 Study